Back to Search
Start Over
[Psychiatry].
- Source :
-
Revue medicale suisse [Rev Med Suisse] 2005 Jan 12; Vol. 1 (2), pp. 159-62, 164-7. - Publication Year :
- 2005
-
Abstract
- The main innovation of the year 2004 was the introduction of a new, second-generation antipsychotic drug with a new mechanism of action (partial dopamine agonist), encouraging first clinical results, and an advantageous clinical tolerance profile. Additionally, three new galenic forms are presented: an oral, extended-release form of methylphenidate that could be useful in the treatment of attention-deficit/hyperactivity disorders; an intramuscular depot form of a second-generation antipsychotic drug (risperidone) with the advantage of improving adherence; and an intramuscular form of a second generation antipsychotic (olanzapine) that is valuable in emergency situations. Finally, we will briefly give an update on the advantages of lamotrigine in bipolar depression.
- Subjects :
- Antidepressive Agents therapeutic use
Antipsychotic Agents therapeutic use
Aripiprazole
Attention Deficit Disorder with Hyperactivity drug therapy
Humans
Lamotrigine
Methylphenidate therapeutic use
Piperazines therapeutic use
Quinolones therapeutic use
Risperidone therapeutic use
Triazines therapeutic use
Mental Disorders drug therapy
Subjects
Details
- Language :
- French
- ISSN :
- 1660-9379
- Volume :
- 1
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Revue medicale suisse
- Publication Type :
- Academic Journal
- Accession number :
- 15773219